UNCY - NASDAQ

Unicycive Therapeutics, Inc.

UNCY·NASDAQ

$7.20

+0.56%

HealthcareBiotechnology

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$154.74M

EPS-1.6700

P/E Ratio-4.31

Earnings Date08/13/2026

-97.37%

Return on Invested Capital

-75%

3Y-101.0%

5Y-98.0%

10Y-116.0%

-87.94%

Return on Equity

-82%

3Y-102.0%

5Y-194.0%

10Y-195.0%

-54.05%

Return on Assets

-53%

3Y-92.0%

5Y-96.0%

10Y-99.0%

Unicycive Therapeutics, Inc. Management Team

UNCY · NASDAQ

Mr. John W. Townsend CPA

Chief Financial Officer

Compensation

$197,864

Born 1962(Age 64)

male

Mr. Douglas Jermasek M.B.A.

Executive Vice President of Corporate Strategy

Compensation

$408,375

Born 1961(Age 65)

male

Dr. Pramod Gupta Ph.D.

Executive Vice President of Pharmaceutical & Business Operations

Compensation

$690,300

Born 1960(Age 66)

Dr. Shalabh K. Gupta M.D., MPA

Founder, Chairman, Chief Executive Officer & President

Compensation

$1,115,400

Born 1974(Age 52)

INSIDER TRANSACTIONS

Unicycive Therapeutics, Inc. Insider Positioning

UNCY · NASDAQ

During the last 12 months, insiders have purchased $2.35M and sold $16K worth of UNCY shares, resulting in $2.33M of net buying activity.

3 Months

Bought

0.00

Sold

0.00

Net Activity

+$0

3-6 Months

Bought

0.00

Sold

0.00

Net Activity

+$0

6-9 Months

Bought

0.00

Sold

0.00

Net Activity

+$0

9-12 Months

Bought

498.6K

2.35M

Sold

3.2K

15.68K

Net Activity

+2.3M

+$2.33M

Top Buyers

GSK

Gupta Shalabh K.

Director, Officer: Ceo

325.0K shares•1 transactions

$1.53M

Gupta Pramod

Officer: Evp, Pharmaceuticals And Bd

90.0K shares•1 transactions

$424K

Aggarwal Gaurav

Director

21.2K shares•1 transactions

$100K

Laumas Sandeep

Director

21.2K shares•1 transactions

$100K

Kenkare-Mitra Sara

Director

21.2K shares•1 transactions

$100K

Top Sellers

Aggarwal Gaurav

Director

3.2K shares•1 transactions

$16K

Insider Activity Analysis

Net Insider Sentiment

Bullish

Strong bullish signal with $2.33M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.

Buy/Sell Ratio

149.82:1

Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.

Insider Participation

High Buying

5 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.

Insider Activity Insight

Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.

SEC PROXY FILINGS

SEC Filings

UNCY - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
DEF 14A DEF 14A 2026 N/A	April 30, 2026	June 19, 2026	2026	View Filing
DEF 14A DEF 14A 2025 N/A	April 30, 2025	June 09, 2025	2025	View Filing
DEF 14A DEF 14A 2024 N/A	April 26, 2024	June 20, 2024	2024	View Filing
DEF 14A DEF 14A 2023 N/A	April 28, 2023	June 26, 2023	2023	View Filing
DEF 14A DEF 14A 2022 N/A	April 19, 2022	June 15, 2022	2022	View Filing

Showing 1 to 5 of 5 filings

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.